Sequence: CRGDKGPDC
| Experiment Id | EXP000727 |
|---|---|
| Paper | Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 e |
| Peptide | iRGD |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 10 mg/kg |
| Rna Concentration | 0.33 mg/kg |
| Mixing Ratio | |
| Formulation Format | co-administration with ROS-sensitive polymeric nanoparticles |
| Formulation Components | iRGD peptide + CA-PLL-TK nanoparticles loaded with siFGL1/siPD-L1 |
| Size Nm | 76.00 |
| Zeta Mv | 6.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | C57BL/6 mouse, LLC tumor model |
| Administration Route | intravenous |
| Output Type | tumor growth inhibition and immune activation |
| Output Value | Significant tumor growth suppression; increased CD4+/CD8+ T cell infiltration |
| Output Units | |
| Output Notes | Dual siRNA + iRGD showed strongest anti-tumor efficacy |
| Toxicity Notes | No significant body weight loss or organ toxicity |
| Curation Notes |